Molecular Diagnostics for Transplant Market Share

Global Molecular Diagnostics for Transplant Market Overview

Molecular Diagnostics for Transplant Market size was valued at USD 0.66 billion in 2021. The Molecular Diagnostics for Transplant Market industry is projected to grow from USD 0.71 billion in 2022 to USD 1.40 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.91% during the forecast period (2024 - 2030).

Increasing prevalence of infectious diseases, rising number of transplant procedures, and advancements in molecular diagnostic techniques are bolstering the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Molecular Diagnostics for Transplant Market Trends

• Increasing prevalence of infectious diseases market growth

There has been an increasing prevalence of infectious diseases owing to various factors such as climate change, rapid urbanization, microbial evolution, among others. Special care needs to be taken before transplantation as a transplant patient can get any type of infection caused by bacteria, viruses, fungi and parasites. These include influenza virus infection, urinary tract infection, pneumococcal pneumonia, Cytomegalovirus, Epstein-Barr virus, Human herpesvirus 6, among several others. Moreover, increasing antimicrobial resistance is also a cause of serious concern and has been adding to the increasing prevalence of infectious disease. For instance, according to the Centers for Disease Control and Prevention, more than 2.8 million antimicrobial-resistant infections occur in the US each year. Thus, increasing prevalence of infectious disease has driven the demand for implementation of thorough molecular diagnostics in transplantation, thereby, driving the market.

Moreover, the number of patients suffering from various types of cancers such as lung, blood, breast, and liver is increasing worldwide. In 2020, according to GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer (IARC), an estimated number of 19.3 million new cancer cases and about 10 million cancer deaths occurred globally.

Hence, the growing number of cancer patients and rising incidences of infectious diseases are increasing the demand for organ transplantation.

Molecular Diagnostics for Transplant Market Segment Insights

Molecular Diagnostics for Transplant Product Insights

The Molecular Diagnostics for Transplant Market segmentation, based on product, includes reagents & kits, instruments, and services & software. The reagents & kits segment held the largest market in 2021, with a market share of 42.77%, and is expected to register the highest CAGR from 2022 to 2030. Molecular diagnostic reagents include disease-specific kits and standard reagents that are used during infectious disease diagnosis and pathogen screening. Laboratory technicians utilize specific disease diagnostic kits for earlier and more precise identification of specific pathogen strains in a patient sample. Standard reagents are key components of the majority of conventional molecular diagnostic procedures. Therefore, companies are now launching rapid reagents & kits to detect the novel coronavirus to fuel the growth of this market.

March 2022 Immucor, Inc. (US) launched innovative transplant diagnostics MIA FORA NGS EXPRESS HLA Typing Software in order to provide a faster and easier NGS analysis experience.

Molecular Diagnostics for Transplant Technology Insights

The Molecular Diagnostics for Transplant Market data has been segmented, based on technology, by polymerase chain reaction (PCR), sequencing, microarray, and others. The polymerase chain reaction (PCR) segment held the largest market in 2021, with a market share of ~35%, reaching a market value of around 0.5 billion by 2030. The sequencing segment is expected to register the highest CAGR of 10.59% from 2022 to 2030. Polymerase Chain Reaction (PCR) technology is used to identify a disease by analyzing the genetic and proteomic parameters such as deoxyribonucleic acid (DNA), and ribonucleic acid (RNA) in humans or the case of infections. Additionally, it plays a crucial role in disease diagnostics and is considered to be one of the most developed molecular techniques which have a wide range of applications in the medicine field and for broad-spectrum pathogen detection and evaluation of emerging novel infections and surveillance.

October 2022: Eurobio Scientific (France) acquired Genome Diagnostics B.V. (Netherlands) for the commercial portfolio of human leukocyte antigen (HLA) diagnostics to assess the compatibility between donors and recipients for organ and marrow transplants.

Figure 2: Molecular Diagnostics for Transplant Market, by Technology, 2023 & 2030 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Molecular Diagnostics for Transplant End User Insights

Based on end user, the global molecular diagnostics for transplant industry has been segmented into the hospitals and transplant centers, research laboratories & academic institutes, and others. The hospitals and transplant centers segment held the largest market in 2021 and is expected to register the highest CAGR of 9.73% from 2022 to 2030. Hospitals and transplant centers witness significant growth due to the rising demand for novel tissue transplantation for treating organ failure, increasing demand for transplant products like tissue products, immunosuppressants, organ preservation solutions, and technological advancements. Healthcare-associated infections  (HAIs) occur in all settings of care, such as ambulatory clinics, hospitals as well as nursing homes, and rehabilitation facilities.

Molecular Diagnostics for Transplant Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America molecular diagnostics for transplant market accounted for the largest market share in 2021, due to rising demand technology evolution and increasing incidences of chronic diseases that lead to an increase in organ transplants. According to research, the number of kidneys, liver, heart, lung, pancreas, and intestine transplants is increasing in the US, while the number of kidney transplants is increasing in Canada.

Further, the major countries studied are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%)  BY REGION 2023

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe molecular diagnostics for transplant market accounts for the second-largest market share owing to the rising prevalence of chronic diseases, including kidney, cardiovascular diseases (CVD), and respiratory diseases. Advancements in molecular diagnostics have improved the identification and understanding of specific gene defects for the appropriate organ transplant in kidney, heart, and lung failure. CVD diseases are influenced by factors such as atherosclerosis, blood clots, diabetes, a sedentary lifestyle, and obesity, which may lead to cardiac failure. In 2019, the European Society of Cardiology (ESC) Atlas estimated that Europe reports 11 million new cases suffering from CVD each year. Furthermore, the Germany molecular diagnostics for transplant market held the largest market share, and the UK molecular diagnostics for transplant market was the second largest to hold the market share in the Europe region.

The Asia-Pacific molecular diagnostics for transplant market is expected to grow at a significant share from 2022 to 2030. The region's growing geriatric population demands organ transplantation, which may vary as per organ failure. In 2020, according to the World Economic Forum, China, India, and Japan had the oldest populations globally. Furthermore, it has been estimated that by 2050, one in four aged people will be living in the region. Moreover, China molecular diagnostics for transplant market held the largest market share, and the India molecular diagnostics for transplant market was the fastest growing market in the Asia-Pacific region.

Molecular Diagnostics for Transplant Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the molecular diagnostics for transplant market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the molecular diagnostics for transplant industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Thermo Fisher Scientific Inc. (US) specializes in various biotechnology products such as analytical instruments, laboratory supply chain programs and e-commerce, laboratory equipment, lab services, and specialty diagnostics. The company helps its customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to the market, and increase the laboratory's productivity. In September 2021, the company announced a new addition to its transplant diagnostics portfolio (a rapid next-generation sequencing assay that will provide high-resolution data in five hours). This new product enabled transplant laboratories to characterize samples better and bring speed and confidence to the transplant laboratory.

Key Companies in the Molecular Diagnostics for Transplant Market includes.

• Thermo Fisher Scientific Inc. (US)


• BioMérieux SA (France)


• Cepheid (US)


• Altona Diagnostics GmbH (Germany)


• ELITechGroup (France)


• Hoffmann-La Roche Ltd. (Switzerland)


• Hologic Inc. (US)


• QIAGEN N.V. (Germany)


• Becton, Dickinson, and Company (US)


• Abbott Laboratories, Inc. (US)


• Others

Molecular Diagnostics for Transplant Industry Developments

October 2022 Eurobio Scientific (France) acquired Genome Diagnostics B.V. (Netherlands) for the commercial portfolio of human leukocyte antigen (HLA) diagnostics to assess the compatibility between donors and recipients for organ and marrow transplants.

February 2022 Bio-Techne Corporation (US) entered into an agreement with Thermo Fisher Scientific, Inc. (US) in order to develop and commercialize the ExoTRU Kidney Transplant Rejection Test.

In September 2021 Thermo Fisher Scientific Inc. (US) announced a new addition to its transplant diagnostics portfolio (a rapid next-generation sequencing assay that will provide high-resolution data in five hours). This new product enabled transplant laboratories to characterize samples better and bring speed and confidence to the transplant laboratory.

Molecular Diagnostics for Transplant Market Segmentation

Molecular Diagnostics for Transplant Product Outlook

• Reagents & Kits


• Instruments


• Services & Software

Molecular Diagnostics for Transplant Technology Outlook

• Polymerase Chain Reaction (PCR)


• Sequencing


• Microarray


• Others

Molecular Diagnostics for Transplant End User Outlook

• Hospitals and Transplant Centers


• Research Laboratories & Academic Institutes


• Others

Molecular Diagnostics for Transplant Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America